Steeply hike registration fees for drugs approval in our country

New Delhi

Pharmaceutical companies may have to shell out more to do business in India. The government has proposed an over five-fold hike in regulatory fees for testing, manufacturing and selling medicines in the country, a move that is likely to impact both domestic as well as multinational pharmaceutical companies operating here.

The health ministry has proposed to increase site registration fee for importing medicines to $10,000 from $1,500. The fees for registration of such imported pharmaceutical products is likely to go up to $5,000 from $1,000. The government has proposed a steep hike even in case of locally manufactured medicines. For any new product registration, companies may have to pay a fee as high as Rs 2,50,000 as compared to Rs 50,000 now.

  • Related Posts

    NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

    The officials identified the substance as Alprazolam manufactured illegally at the lab. HYDERABAD: In one of the largest such seizures in recent times, the Narcotics Control Bureau (NCB), Hyderabad, raided…

    Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

    New Delhi: The Ministry of AYUSH has detailed its regulatory framework and ongoing initiatives to monitor heavy metal content in traditional medicines, responding to parliamentary concerns over quality and safety…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

    Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

    Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

    Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

    AstraZeneca Pharma India opens new Mumbai corporate office, marking the next phase of growth through innovation

    AstraZeneca Pharma India opens new Mumbai corporate office, marking the next phase of growth through innovation

    Pharmaceuticals export reports around 4.9 per cent growth in H1 FY27

    Pharmaceuticals export reports around 4.9 per cent growth in H1 FY27

    NDLEA Intercepts Massive ₦6.98 Billion Tramadol Shipment Imported from India at Lagos Port

    NDLEA Intercepts Massive ₦6.98 Billion Tramadol Shipment Imported from India at Lagos Port

    Two More Pregnant Women In Rajasthan’s Kota Die From Kidney Complications

    Two More Pregnant Women In Rajasthan’s Kota Die From Kidney Complications